Here, Malek and colleagues describe the multiple ways in which IL-2 biologics have been engineered to preferentially target regulatory T cells or effector T cells, memory T cells and natural killer cells to correct dysregulated or insufficient immune responses in the settings of autoimmunity or cancer.
- Rosmely Hernandez
- Janika Põder
- Thomas R. Malek
